{"disease":{"id":"onychomycosis-due-to-trichophyton-mentagrophytes","name":"Onychomycosis due to Trichophyton mentagrophytes","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"efinaconazole","indication_name":"Onychomycosis due to Trichophyton mentagrophytes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jublia","generic_name":"EFINACONAZOLE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":"Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03072550","title":"Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"DeviceFarm, Inc.","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}